You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Jazz Pharmaceuticals reported record revenue of $1.24 billion, up 10%, and raised 2026 revenue guidance to 4.775 to 4.85 billion dollars. Zihara generated $21 million and has peak sales potential of $3 to $5 billion.
Jazz Pharmaceuticals plc reported approximately 17,550 active Xywav patients exiting the third quarter of 2026, FDA approval of two first-line Ziihera GEA regimens in August 2026, and Zepzelca’s second-line indication removal on September 30, 2026.
Jazz Pharmaceuticals reported record 3Q26 revenue of $1.2 billion (+10% YoY), raised 2026 revenue guidance to $4.775 - $4.85 billion, and closed the Actio acquisition in September 2026, adding ABS-1230 (JZP6979) to its rare epilepsy portfolio.
Jazz Pharmaceuticals estimates the Actio Biosciences acquisition, completed September 15, 2026, will produce a pre-tax acquired IPR&D charge of approximately $755 million in the third quarter of 2026, unfavorable by approximately $11.00 to both GAAP EPS and non-GAAP adjusted EPS.
Jazz Pharmaceuticals plc announced Samantha Pearce plans to retire as Chief Commercial Officer upon selection and appointment of her successor or by June 30, 2027, and will search internal and external candidates.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Jazz delivered record Q3 revenue, raised revenue and gross-margin guidance, and reported strong Zihara launch traction and overall-survival data. Key risks include gross-margin compression, the Actio IPR&D charge, Zepselka competition and label removal, Epidiolex growth pressure, a measured near-term Medeso pace, and possible rare-sleep initiation delays.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active patients (Xywav) | 17,125 | exiting the quarter 2Q26 | — |
| Active patients with IH (Xywav) | 5,850 | exiting the quarter 2Q26 | — |
| Active patients with narcolepsy (Xywav) | 11,275 | exiting the quarter 2Q26 | — |
| Cash from operations (six months) | $824M | six months ended June 30, 2026 | — |
| Epidiolex/Epidyolex volume growth | 12% | the three months ended June 30, 2026 filing | — |
| Modeyso patients received from launch | 600 | August 2025 through the end of 2Q26 | — |
| Non-GAAP adjusted diluted EPS non-GAAP | $12.04 | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted effective tax rate non-GAAP | 12.4% | Six months ended June 30, 2026 | — |
| Non-GAAP adjusted gross margin non-GAAP | 91.9% | Six months ended June 30, 2026 | — |
| Non-GAAP adjusted net income non-GAAP | 815.9M | Six Months Ended June 30, 2026 | — |
| Xyrem volume decline | 20% | the three months ended June 30, 2026 filing | — |
| Xywav net patient adds | 525 | 2Q26 | — |
| Xywav volume growth | 12% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JAZZ
this stock
Jazz Pharmaceuticals plc
|
$15.50B | +42.1% | +8.8% | 78.7 | 9.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Jazz Pharmaceuticals plc reported approximately 17,550 active Xywav patients exiting the third quarter of 2026, FDA approval of two first-line Ziihera GEA regimens in August 2026, and Zepzelca’s second-line indication removal on September 30, 2026.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JAZZ | +2.9% | +14.9% | +1.7% | +11.8% | +42.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.3% | +16.1% | +1.2% | +12.0% | +31.5% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
